-
ABOUT USThe company is a professional API manufacturer established and developed by Shijiazhuang No.4 Pharmaceutical Group to actively promote the development strategy of "API + preparation"
-
INNOVATIONDevelops fine, series, high-end API and innovative API intermediates with high added value through overcoming key technologies such as API synthesis to build variety competition advantages.
-
PRODUCTSWith the annual production 500MT of hydroxyethyl starch , 500MT of azithromycin , we are ranking in the API professional enterprises in Hebei Province and even in China .
-
RECRUITGuolong has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities
-
CONTACTAdhering to the "love the people with quality, formed the base with integrity" business philosophy, is committed to developing the domestic high-end market and the international market.
Good news keeps coming! Shijiazhuang No.4 Pharmaceutical Group’s specialty active pharmaceutical ingredient, rosuvastatin calcium, has been approved.
Category:
Time:2022-06-23
【概要描述】
On June 23, the active pharmaceutical ingredient—rosuvastatin calcium—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Four Pharmaceutical Group, was approved by the National Medical Products Administration and has been registered as an active pharmaceutical ingredient for use in marketed formulations.
On June 23, the active pharmaceutical ingredient—rosuvastatin calcium—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed formulations. This is the eighth special API variety that Shijiazhuang Fourth Pharmaceutical Group has obtained production approval for this year since implementing its “API + Finished Dosage Form” product strategy.
It is understood that rosuvastatin calcium is primarily used for the treatment of primary hypercholesterolemia or mixed dyslipidemia. Previously, the group had already obtained drug registration approvals from the National Medical Products Administration for two specifications of rosuvastatin calcium tablets (5 mg and 10 mg).
Over the past two years, Shijiazhuang No.4 Pharmaceutical has aligned its innovation chain with the industrial chain. The company’s R&D investment now accounts for nearly 10% of its main business revenue. Through continuous optimization of its research system and talent development initiatives, the company has entered a period of concentrated “harvest” in scientific and technological innovation, effectively accelerating its journey toward innovative development. As of now, this year alone, the company has been approved for 21 new product projects covering both finished dosage forms and active pharmaceutical ingredients—averaging more than three per month. The number and efficiency of its specialty generic drug and API development rank among the top in the domestic industry, strongly supporting the company’s move toward the high end of the value chain.
Keywords:
Recommended
Share to
SERVICE HOTLINE
Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province
Mobile site
E code
Business license